Gossamer Bio Annual Revenue, Competitors, Number of Employees and Funding
Estimated Revenue & Financials
- Gossamer Bio's estimated annual revenue is currently $6M per year.
- Gossamer Bio received $230.0M in venture funding in July 2018.
- Gossamer Bio's estimated revenue per employee is $35,769
- Gossamer Bio's total funding is $480M.
- Gossamer Bio has 169 Employees.
- Gossamer Bio grew their employee count by 34% last year.
- Gossamer Bio currently has 12 job openings.
|Derek Moe||Senior Director Product Development||Email Available|
|David Ansonoff||Director Data Management||Email Available|
|Karen Dittrich||Exec Director, Project Team Leader||Email Available|
|Aaron Hasnain||Director, Business Development||Email Available|
|Isharat Yusuf||Associate Director, Pharmacology||Email Available|
|Isabelle Lerario||Research Program Manager||Email Available|
|Rebecca Tran||Senior Manager Clinical Operations|
|Fahmi Al-Aqrabi||Senior Manager, Drug Product|
|Jennifer Woo||Associate Director||Email Available|
|David Nickle||Senior Director||Email Available|
What Is Gossamer Bio?
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio's strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$27.6M||178||8%||N/A|
|Full Spectrum A...||$6.5M||42||5%||N/A|
Gossamer Bio News
Investors in Gossamer Bio, Inc. GOSS need to pay close attention to the stock based on moves in the options market lately. That is because the ...
Artal Group S.A. trimmed its position in Gossamer Bio Inc (NASDAQ:GOSS) by 3.0% in the 2nd quarter, according to the company in its most ...
Some Gossamer Bio, Inc. (NASDAQ:GOSS) shareholders may be a little concerned to see that the Chief Scientific Officer, Luisa Salter-Cid, ...
Gossamer Bio Funding
Gossamer Bio Executive Hires
|2018-07-24||Sheila Gujrathi||Chief Executive Officer, and Co-Founder||Article|
|2018-09-06||Luisa Salter-Cid||Chief Scientific Officer||Article|
|2018-12-18||Jakob Dupont||Chief Medical Officer||Article|